DanDi Bioscience

https://view.asiae.co.kr/article/2022092310232513818  

This post has been translated from the original article dated 9/23/2022. 

[Asia Economy Correspondent Lee Chun-hee] HLB Science presented the results of basic and pre-clinical research on 'DD-S052P', a new drug candidate for sepsis treatment, in the form of a poster at the Korean Society for Molecular and Cell Biology (KSMCB) to be held at the Jeju International Convention Center on the 28th and 30th. announced on the 23rd.

HLB Science is developing the low-toxic synthetic peptide DD-S052P, which has a mechanism to neutralize endotoxin as well as killing bacteria by combining with LPS, as a next-generation sepsis treatment. The company explained, "According to the preclinical results, in an experiment using uninfected organs as a control, it was effective in removing bacteria from infected organs and lowering LPS and inflammatory cytokine levels to normal levels."

In July, HLB Science received approval from the French Ministry of Food and Drug Safety (ANSM) for a phase 1 clinical trial plan (IND) for DD-S052P to develop new drugs for sepsis and gram-negative superbacterial infections. Clinical trials will be conducted at Eurofiins Optimed in France. The company plans to confirm the safety, tolerability and blood pharmacokinetics of ‘DD-S052P’, a next-generation sepsis treatment that kills bacteria and neutralizes endotoxin through phase 1.

Park Young-min, CEO of HLB Science, said, “Sepsis is a serious disease with a mortality rate of 30-50% because there is no cure for 11 million people dying every year.” It can treat sepsis caused by inflammatory diseases.”

Reporter Lee Chun-hee spring@asiae.co.kr